1108 / 1708
SIOP WT 2001
Pritchard-Jones et al SIOP Abstract 2011
Pediatric Blood and Cancer
57 (5), 741, 2011
•
Can doxorubicin be safely omitted from
chemotherapy for stage II/III, intermediate risk
WT?
•
SIOP multicentre trial (28 countries, 261 centres)
•
4 weeks pre-op VCR /ActD, delayed nephrectomy
•
Stage II/III intermediate risk WTs were
randomized between 26 weeks AV or AVD (total
Doxo 250 mg/m2)
•
Stage III tumours received 14.4 Gy flank RT